CA2317811A1 - Treatment of dyskinesias - Google Patents

Treatment of dyskinesias Download PDF

Info

Publication number
CA2317811A1
CA2317811A1 CA002317811A CA2317811A CA2317811A1 CA 2317811 A1 CA2317811 A1 CA 2317811A1 CA 002317811 A CA002317811 A CA 002317811A CA 2317811 A CA2317811 A CA 2317811A CA 2317811 A1 CA2317811 A1 CA 2317811A1
Authority
CA
Canada
Prior art keywords
riluzole
levodopa
dyskinesia
patients
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002317811A
Other languages
English (en)
French (fr)
Inventor
Eldad Melamed
Ruth Djaldetti
Ilan Ziv
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mor Research Applications Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL12288398A external-priority patent/IL122883A0/xx
Priority claimed from IL12710298A external-priority patent/IL127102A0/xx
Application filed by Individual filed Critical Individual
Publication of CA2317811A1 publication Critical patent/CA2317811A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CA002317811A 1998-01-09 1999-01-05 Treatment of dyskinesias Abandoned CA2317811A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IL122883 1998-01-09
IL12288398A IL122883A0 (en) 1998-01-09 1998-01-09 Pharmaceutical compositions for the treatment of dyskinesias
IL127102 1998-11-17
IL12710298A IL127102A0 (en) 1998-11-17 1998-11-17 Pharmaceutical compositions for the treatment of dyskinesias
PCT/IL1999/000003 WO1999034785A2 (en) 1998-01-09 1999-01-05 Treatment of dyskinesias

Publications (1)

Publication Number Publication Date
CA2317811A1 true CA2317811A1 (en) 1999-07-15

Family

ID=26323572

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002317811A Abandoned CA2317811A1 (en) 1998-01-09 1999-01-05 Treatment of dyskinesias

Country Status (10)

Country Link
EP (1) EP1043996A2 (ja)
JP (1) JP2002500181A (ja)
KR (1) KR20010033978A (ja)
CN (1) CN1290166A (ja)
AU (1) AU1780699A (ja)
BR (1) BR9906821A (ja)
CA (1) CA2317811A1 (ja)
NO (1) NO20003529L (ja)
PL (1) PL342098A1 (ja)
WO (1) WO1999034785A2 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1161238A1 (fr) * 1999-03-12 2001-12-12 Aventis Pharma S.A. Traitement de la sclerose laterale amyotrophique avec une association de riluzole et d'un antagoniste des recepteurs ampa
FR2790670A1 (fr) * 1999-03-12 2000-09-15 Aventis Pharma Sa Association riluzole et antagoniste des recepteurs ampa
US6297254B1 (en) 1999-12-01 2001-10-02 Aventis Pharma S. A. Method for the prevention or treatment of a motoneuron disease
FR2801793B1 (fr) * 1999-12-01 2003-07-04 Aventis Pharma Sa Association d'une ergoline et de riluzole et son utilisation comme medicament
FR2809620B1 (fr) * 2000-06-05 2002-08-02 Aventis Pharma Sa Utilisation du riluzole ou ses sels pour la prevention et le traitement de l'adrenoleucodystrophie
ES2203563T3 (es) * 2001-05-08 2004-04-16 Schwarz Pharma Ag Sistema terapeutico transdermico mejorado para el tratamiento de la enfermedad de parkinson.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.

Also Published As

Publication number Publication date
WO1999034785A3 (en) 1999-09-16
CN1290166A (zh) 2001-04-04
JP2002500181A (ja) 2002-01-08
NO20003529L (no) 2000-09-08
PL342098A1 (en) 2001-05-21
KR20010033978A (ko) 2001-04-25
NO20003529D0 (no) 2000-07-07
AU1780699A (en) 1999-07-26
BR9906821A (pt) 2000-10-17
WO1999034785A2 (en) 1999-07-15
EP1043996A2 (en) 2000-10-18

Similar Documents

Publication Publication Date Title
US10980760B2 (en) Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
US20090137565A1 (en) Method for treatment of movement disorders
KR102630701B1 (ko) 두개 신경의 약리학적 피부 활성화에 의한 신경변성 질환과 관련된 증상의 치료
JP2005527599A (ja) 肥満および摂食障害におけるゾニサミドの使用
AU2002340971B2 (en) Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders
DE19818563C2 (de) Verwendung von alpha-Liponsäure zur Verringerung des Appetits und/oder zur Körpergewichtsreduzierung
US6417210B1 (en) Treatment of dyskinesias and Parkinson's disease with riluzole and levodopa
CA2317811A1 (en) Treatment of dyskinesias
CN114432266A (zh) 一种稳定的盐酸环苯扎林缓释胶囊
Rudick et al. Drug treatment of multiple sclerosis
MXPA00006800A (en) Treatment of dyskinesias
ZA200509665B (en) Use of tripolidine in a providing refreshedness on waking
CN114786660A (zh) 使用mtorc1调节剂的治疗方法
CN117500490A (zh) 用于治疗执行功能障碍的组合治疗

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead